Bavarian Nordic ends cancer vaccine program to fully focus on profitable infectious disease range

Bavarian Nordic may be celebrating its most profitable year yet on the back of mpox vaccine sales, but that hasn’t stopped the Danish biotech from streamlining its portfolio.